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Abstract
Most classical preclinical tests to predict antidepressant activity were initially developed to detect
compounds that inﬂuenced noradrenergic and/or serotonergic activity, in accordance with the
monoaminergic hypothesis of depression. However, central opioid systems are also known to inﬂuence
the pathophysiology of depression. While the tail suspension test (TST) is very sensitive to several types of
antidepressant, the traditional form of scoring the TST does not distinguish between diﬀerent modes
of action. The present study was designed to compare the behavioural eﬀects of classical noradrenergic
and/or serotonergic antidepressants in the TST with those of opioids. We developed a sampling
technique to diﬀerentiate between behaviours in the TST, namely, curling, swinging and immobility.
Antidepressants that inhibit noradrenaline and/or serotonin re-uptake (imipramine, venlafaxine,
duloxetine, desipramine and citalopram) decreased the immobility of mice, increasing their swinging but
with no eﬀect on their curling behaviour. No diﬀerences were observed between antidepressants that act
on noradrenergic or serotoninergic transmission. While opioid compounds also decreased the immobility
of the mice [morphine, codeine, levorphanol, (x)-methadone, (¡)-tramadol and (+)-tramadol], they
selectively increased curling behaviour. Blocking opioid receptors with naloxone prevented the anti-
depressant-like eﬀect of codeine, and m-opioid receptor knockout decreased normal curling behaviour and
blocked (¡)-tramadol-induced curling, further demonstrating the reliability and validity of this approach.
These results show that at least two behaviourally distinct processes occur in the TST, highlighting the
antidepressant-like eﬀects of opioids evident in this test. Furthermore, our data suggest that swinging and
curling behaviours are mediated by enhanced monoamine and opioid neurotransmission, respectively.
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Introduction
There is substantial evidence implicating the opioid
system in depression (Hegadoren et al. 2009), sug-
gesting that compounds that enhance opioid
neurotransmission may exert genuine antidepressant
eﬀects (Berrocoso & Mico, 2009a ; Jutkiewicz, 2006 ;
Tejedor-Real et al. 1998). Since the description of the
‘opium cure’ (Kraepelin, 1901), clinical reports have
described the eﬀectiveness of m-opioid receptor (MOR)
agonists in patients suﬀering depression, such as oxy-
codone, oxymorphone, tramadol and buprenorphine,
especially in cases of refractory depression (Bodkin
et al. 1995; Fanelli & Montgomery, 1998 ; Shapira et al.
2001; Spencer, 2000 ; Stoll & Rueter, 1999). We have
studied the antidepressant-like eﬀects of opioids and,
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in accordance with other studies (reviewed in
(Berrocoso et al. 2009), we demonstrate the anti-
depressant-like activity of several opioids in animal
paradigms of depression (Rojas-Corrales et al. 1998,
2004 ; Tejedor-Real et al. 1998). Indeed, we previously
described a functional interaction between opioids
and selective serotonin reuptake inhibitors (SSRIs) or
noradrenaline (NA) reuptake inhibitors in the tail
suspension test (TST: Berrocoso & Mico, 2009a),
whereby both opioids and the more classic anti-
depressants decrease the time that the mice spend
immobile (consistent with an antidepressant-like
eﬀect).
The mouse TST is a predictive behavioural test of
antidepressant activity (Chermat et al. 1986; Steru et al.
1985, 1987) that is being increasingly used with the
advent of transgenic mice. When mice are suspended
by the tail they are subjected to short-term inescapable
stress and they adopt an immobile posture. However,
if antidepressant treatments are administered prior to
the test, the mice will actively pursue escape-directed
behaviours over longer periods of time. The increase
in such activity (i.e. the decrease in immobility) in the
TST is strongly correlated with antidepressant eﬀects
in humans (Cryan et al. 2005a). This clinical predictive
value, together with the high degree of reliability in
diﬀerent laboratories, has led to the inclusion of the
TST in almost all batteries used to screen new anti-
depressant drugs (Bravo et al. 2009), even though
the TST in its traditional form cannot reliably detect
speciﬁc modes of drug action. In our laboratory,
previous studies with the TST suggested that while
opioids decrease the time mice spend immobile they
induce a pattern of activity that diﬀers from that seen
with classical monoaminergic antidepressants. To
further investigate this eﬀect, we have systematically
analysed the behaviour of mice in the TST to compare
the active behaviours induced by classical anti-
depressants and opioids.
Materials and method
Animals
Experiments were performed using male albino
CD1 mice, male and female wild-type mice or hetero-
zygous and homozygous MOR knockout (MOR-KO)
littermates obtained by crossing heterozygous/
heterozygous MOR-KO mice on a C57BL/6J genetic
background (Sora et al. 2001). Animals were main-
tained under standard conditions : 12-h light/dark
cycle (lights on 08:00 hours), ad libitum access to food
and water and a constant temperature (21¡1 xC).
Animals were housed in groups of 10 in standard
polypropylene cages (1000 cm2) and male and female
mice shared the same room. All animal handling
and procedures were performed in accordance with
the European Communities directive 86/609-EEC and
Spanish Law (RD 1201/2005) regulating animal re-
search. The experimental protocols were approved by
the Committee for Animal Experimentation of the
University of Ca´diz. All mice were experimentally
naive, they weighed 25–30 g at the time of testing and
they were only used once.
Drugs
The following drugs were used in this study: imipra-
mine, desipramine, codeine and naloxone (Sigma-
Aldrich-Quimica, UK) ; venlafaxine (Wyeth, USA);
duloxetine (Eli Lilly, USA); citalopram, (¡)-tramadol
and (+)-tramadol (Gru¨nenthal, Germany and Spain) ;
morphine (Agencia Espan˜ola de Medicamentos y
Productos Sanitarios, Spain) ; (x)-methadone and
levorphanol (RBI, USA). The selectivity of these com-
pounds for opioid receptors (m, d and k) and mono-
amine transporters (5-HT and NA) is summarized in
Table 1.
All the drug solutions were prepared immediately
before each trial and they were injected i.p., with the
exception of naloxone, which was administered sub-
cutaneously. All drugs were dissolved in physio-
logical saline (NaCl 0.9%), with the exception of
duloxetine, which was dissolved in distilled water,
and the control animals received saline alone (NaCl
0.9%). All the solutions were injected in a volume of
10 ml/kg body weight 30 min prior to testing and the
treatments were administered under blind conditions.
Tail suspension test
We used a modiﬁed form of the TST that was pre-
viously validated for NMRI mice (Steru et al. 1985).
Accordingly, 30 min after injection the mice were
individually suspended by the tail from an aluminium
hook raised 20 cm above the ﬂoor using adhesive tape
placed 2 cm from the tip of tail. The mice were posi-
tioned such that the base of their tail was aligned with
the horizontal plane. Typically, mice demonstrated
escape-oriented behaviour interspersed with success-
ively longer bouts of immobility. Test sessions lasted
for 6 min and they were videotaped and subsequently
scored by a trained observer.
Behavioural scoring
The procedure used to analyse the test sessions was
similar to that described previously for the forced
152 E. Berrocoso et al.
swimming test (FST; Detke et al. 1995). A time-
sampling technique was employed, whereby the pre-
dominant behaviour in each 5-s period of the 360 s
test was recorded. The behaviours rated were: (1)
immobility – a mouse was judged to be immobile
when it hung by its tail without engaging in any active
behaviour ; (2) swinging – a mouse was judged to
be swinging when it continuously moved its paws in
the vertical position while keeping its body straight
and/or it moved its body from side to side; (3) curling –
a mouse was judged to be curling when it engaged in
active twisting movements of the entire body (Fig. 1).
The behavioural scoring was performed by a single
experienced observer who was blind to the treatments.
Several test sessions (n=30 subjects) were then scored a
second time by the observer to determine the test–retest
reliability (i.e. two consecutive ratings by the same
observer were compared). These sessions were then
scored by a second blind observer to determine the
inter-rater reliability.
Statistical analysis
The data were expressed as the mean+S.E.M. of the
parameter measured and they were analysed by one-
way analysis of variance (ANOVA) followed by the
Table 1. Summary of the inhibitory eﬀects of antidepressants and opioids on monoamine uptake and opioid receptor binding
Drugs m d k NA 5-HT Reference
Antidepressants
Imipramine 3700 12 700 1800 6.6 21 Raﬀa et al. (1992)
Venlafaxine – – – 1260 74 Beique et al. (1998)
Duloxetine – – – 3 1.8 Beique et al. (1998)
Desipramine – – – 0.31 129 Owens et al. (1997)
Citalopram – – – 3042 0.75 Owens et al. (1997)
Opioids
With no reuptake-inhibiting activity
Morphine 0.34 92 570 IA IA Raﬀa et al. (1992)
Codeine 160 5130 5970 IA IA Raﬀa et al. (1992)
With reuptake-inhibiting activity
Levorphanol 0.42 3.61 4.2 1220 86.3 Codd et al. (1995)
(x)-Methadone 0.945 371 1860 702 14.1 Codd et al. (1995)
(¡)-Tramadol 2100 57 600 42 700 709 990 Raﬀa et al. (1992)
(+)-Tramadol 1300 62 400 54 000 2510 530 Raﬀa et al. (1993)
NA, Noradrenaline ; IA, inactive at 10 mM.
The assays were performed on rat brain samples and the data represent Ki values¡S.E.M. (nM).
(a) (b) (c)
Fig. 1. Photographs illustrating the behaviours scored in the tail suspension test. (a) Immobility – the mouse hangs without
engaging in any activity ; (b) swinging – keeping its body straight, the mouse continuously moves its paws in a vertical position
and/or moves its body from side to side ; (c) curling – the mouse engages in active twisting movements.
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Dunnett’s (for dose–response studies) or Tukey’s test.
For the mechanistic studies, the data were analysed
using a two-way ANOVA followed by the Bonferrroni
post-hoc test. The factors evaluated (between subjects)
were codeine/(¡)-tramadol treatment and naloxone
treatment. A Pearson’s correlation test was used to
determine test–retest and inter-rater reliability and
p<0.05 was considered statistically signiﬁcant.
Results
In the TST employed here, the reliability of the scoring
for each of the three behaviours contemplated was
very high. Moreover, the test–retest reliabilities were :
r=0.89 for immobility ; r=0.93 for swinging ; r=0.88
for curling. The concordance between raters was:
r=0.92 for immobility ; r=0.86 for swinging ; r=0.81
for curling (p<0.0001).
Antidepressants
All the antidepressants administered here induced
similar behavioural changes in the TST, reducing
the immobility in conjunction with an increase in
swinging, exerting no eﬀect on curling behaviour
[see Table 2(a–e) for one-way ANOVA data]. For
example, the tricyclic antidepressant imipramine
(2.5–20.0 mg/kg) induced a dose-dependent decrease
in immobility while increasing swinging behaviour
at both 10 and 20 mg/kg (p<0.05 in all cases), without
aﬀecting curling behaviour (Fig. 2a). The 5-HT and
NA reuptake inhibitors venlafaxine (2.5–20.0 mg/kg)
and duloxetine (1.25–40.0 mg/kg) induced similar
behavioural changes, signiﬁcantly decreasing im-
mobility and increasing swinging behaviour in a
dose–dependent manner. Moreover, like imipramine,
neither venlafaxine nor duloxetine altered curling
Table 2. Eﬀects of antidepressants and opioids on immobility and active behaviours in the tail suspension test
Drugs Immobility Swinging Curling
Antidepressants
(a) Imipramine F4,44=3.34, p<0.05 F4,44=3.55, p<0.05 F4,44=0.69, n.s.
(b) Venlafaxine F4,42=7.82, p<0.001 F4,42=3.30, p<0.05 F4,42=0.13, n.s.
(c) Duloxetine F6,63=3.77, p<0.01 F6,63=2.33, p<0.05 F6,63=0.71, n.s.
(d) Desipramine F3,32=6.43, p<0.01 F3,32=4.13, p<0.05 F3,32=2.79, n.s.
(e) Citalopram F5,51=4.25, p<0.01 F5,51=2.70, p<0.05 F5,51=1.64, n.s.
Opioids
(f) Morphine F3,36=5.36, p<0.01 F3,36=12.02, p<0.001 F3,36=26.78, p<0.001
(g) Codeine F3,35=3.13, p<0.05 F3,35=3.70, p<0.05 F3,35=9.35, p<0.001
(h) Levorphanol F5,51=3.14, p<0.05 F5,51=7.15, p<0.001 F5,51=13.52, p<0.001
(i) (x)-Methadone F3,36=3.44, p<0.05 F3,36=3.61, p<0.05 F3,36=8.61, p<0.001
(j) (¡)-Tramadol F3,36=5.01, p<0.01 F3,36=0.72, n.s. F3,36=5.85, p<0.01
(k) (+)-Tramadol F3,33=6.60, p<0.01 F3,33=4.01, p<0.05 F3,33=12.38, p<0.001
Pharmacological opioid receptor blockade
(l) Codeine F1,54=7.93, p<0.01 F1,54=2.19, n.s. F1,54=3.20, n.s.
(m) Naloxone F2,54=0.70, n.s. F2,54=12.23, p<0.001 F2,54=16.26, p<0.001
(n) Codeinernaloxone F2,54=3.25, p<0.05 F2,54=4.09, p<0.05 F2,54=6.11, p<0.01
MOR knockout
(o) Gender F1,57=0.32, n.s. F1,57=1.23, n.s. F1,57=0.02, n.s.
(p) Genotype F2,57=0.28, n.s. F2,57=1.23, n.s. F2,57=3.50, p<0.05
(q) Genderrgenotype F2,57=0.73, n.s. F2,57=0.86, n.s. F2,57=0.12, n.s.
(r) Genotype F2,60=0.14, n.s. F2,60=1.50, n.s. F2,60=3.75, p<0.05
(s) (¡)-Tramadol F2,180=45.44, p<0.001 F2,180=8.78, p<0.001 F2,180=21.31, p<0.001
(t) Genotype F2,180=0.54, n.s. F2,180=4.93, p<0.01 F2,180=14.18, p<0.001
(u) (¡)-tramadolrgenotype F4,180=0.25, n.s. F4,180=1.19, n.s. F4,180=2.48, p<0.05
(v) (¡)-tramadol-WT F2,50=17.95, p<0.001 F2,50=2.84, n.s. F2,50=6.32, p<0.01
(w) (¡)-tramadol-HET F2,68=24.07, p<0.001 F2,68=0.61, n.s. F2,68=16.70, p<0.001
(x) (¡)-tramadol-KO F2,62=9.77, p<0.001 F2,62=6.12, p<0.01 F2,62=1.59, n.s.
MOR, m-opioid receptor ; WT, wild-type ; HET, heterozygous ; KO, knockout.
p values and F values from one- and two-way analysis of variance tests, respectively, are shown.
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behaviour (Fig. 2b, c). In a dose–response study to
assess the antidepressant-like eﬀects of the NA uptake
inhibitor desipramine (2.5–10.0 mg/kg), 10 mg/kg
desipramine reduced the time spent immobile
(p<0.01) while increasing swinging (p<0.05), pro-
ducing no eﬀect on curling behaviour (Fig. 2d).
Finally, the selective 5-HT uptake inhibitor citalopram
(5–80 mg/kg) induced a behavioural pattern similar to
that of the other antidepressants tested, decreasing
immobility at 80 mg/kg (p<0.05) while increasing
swinging behaviour (p<0.05), with no eﬀect on curl-
ing behaviour (Fig. 2e).
Opioids
All the opioids tested induced a similar behavioural
pattern in the TST, decreasing immobility while
increasing curling behaviour [see Table 2(f–k) for
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Fig. 2. Eﬀects of (a) imipramine (2.5–20 mg/kg i.p.), (b) venlafaxine (2.5–20 mg/kg i.p.), (c) duloxetine (1.25–40 mg/kg i.p.),
(d) desipramine (2.5–10 mg/kg i.p.) and (e) citalopram (5–80 mg/kg i.p.) on immobility and active behaviours in the tail
suspension test. Drugs were administered 30 min before testing and the data represent the mean counts+S.E.M. from
8–11 animals per group. There were signiﬁcant diﬀerences when compared to saline-treated mice (Dunnett’s post-hoc test :
* p<0.05 ; ** p<0.01 ; *** p<0.001).
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one-way ANOVA data]. Opioids that do not inhibit
monoamine reuptake, such as morphine (10–40 mg/
kg), attenuated immobility and swinging behaviour in
a dose–dependent manner, while robustly increasing
curling behaviour (Fig. 3a). Similar eﬀects were ob-
served for codeine (10–40 mg/kg), which as reported
elsewhere (Berrocoso & Mico, 2009a), reduced im-
mobility at 40 mg/kg (p<0.05), decreased swinging
(p<0.05) and increased curling behaviour when
administered at 20 or 40 mg/kg (p<0.01 and p<0.001,
respectively ; Fig. 3b). Opioids with monoamine
uptake-inhibiting activity such as levorphanol (0.03–
10.00 mg/kg) and (x)-methadone (1.25–5.00 mg/kg)
induced a behavioural pattern similar to that seen for
morphine and codeine, signiﬁcantly reducing immo-
bility (p<0.05 in both cases) and swinging behaviour
and increasing curling behaviour (Fig. 3c, d). The
behaviour elicited in response to (¡)-tramadol
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Fig. 3. Eﬀects of (a) morphine (10–40 mg/kg i.p.), (b) codeine (10–40 mg/kg i.p.), (c) levorphanol (0.03–10 mg/kg i.p.),
(d) (x)-methadone (1.25–5 mg/kg i.p.), (e) (¡)-tramadol (16–64 mg/kg i.p.) and (f) (+)-tramadol (16–64 mg/kg i.p.) on
immobility and active behaviour in the tail suspension test. Drugs were administered 30 min before testing and the data
represent the mean counts+S.E.M. from 8–10 animals per group. There were signiﬁcant diﬀerences when compared to
saline-treated mice (one-way analysis of variance followed by Dunnett’s post-hoc test : * p<0.05 ; ** p<0.01 ; *** p<0.001).
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(16–64 mg/kg) diﬀered slightly from that provoked by
the other opioids (Fig. 3e) and, speciﬁcally, a signiﬁ-
cant reduction in immobility (p<0.05) and an increase
in curling behaviour (p<0.01) at 32 and 64 mg/kg was
not coupled with any eﬀect on swinging behaviour.
By contrast, the dextro enantiomer (+)-tramadol,
which binds to the MOR and inhibits 5-HT reuptake
more strongly than (¡)-tramadol (Raﬀa et al. 1993),
produced similar eﬀects to the other opioids studied
(Fig. 3 f), decreasing immobility and increasing curling
behaviour at 32 and 64 mg/kg and decreased swing-
ing at 64 mg/kg (p<0.01 ; Fig. 3 f).
Role of opioid receptors in antidepressant-like eﬀects
Pharmacological blockage
To conﬁrm the role of the opioid system in curling
behaviour, an eﬀective dose of codeine (40 mg/kg)
was co-administered with the opioid receptor antag-
onist, naloxone [0.5–2.0 mg/kg; Fig. 4, Table 2(l–n)].
Two-way ANOVA revealed a signiﬁcant eﬀect of co-
deine on immobility (p<0.01), while swinging and
curling behaviour remained unchanged. Two-way
ANOVA also revealed signiﬁcant eﬀects of naloxone
on swinging (p<0.0001) and curling behaviours
(p<0.001). Furthermore, a signiﬁcant interaction be-
tween factors was observed for all three behaviours :
immobility (p<0.05) ; swinging (p<0.05) ; curling
(p<0.01). Indeed, a Bonferroni’s analysis revealed that
naloxone signiﬁcantly blocked the eﬀects of codeine
on immobility, swinging and curling (p<0.01 in all
cases ; Fig. 4).
MOR-KO study
To determine whether curling behaviour involves the
activation of MORs, we evaluated the behaviour of
C57BL/6J MOR-KO mice in the TST, both males and
females. Initially, we investigated the eﬀects of gender
and genotype [Table 2(o–q)] and while a two-way
ANOVA revealed no signiﬁcant eﬀect of gender and
no genderrgenotype interaction, a signiﬁcant eﬀect
of genotype was evident [p<0.05, Table 2(p)]. As
expected, a subsequent unpaired Student’s t test re-
vealed no signiﬁcant diﬀerence in behaviour between
male and female knockout mice (data not shown).
Thus, the data from the male and female mice were
pooled for the subsequent studies. While we were
unable to detect any diﬀerences in the behaviour of
heterozygous MOR-KO mice from their wild-type
littermates, the homozygous knockout mice displayed
signiﬁcantly less curling behaviour compared to their
wild-type littermates [p<0.05, Tukey’s test ; Fig. 5,
Table 2(r)]. This result supports the hypothesis that
curling behaviour involves MOR activation.
The opioid (¡)-tramadol acts through both MOR
and 5HT/NA transporters and, hence, we explored
its eﬀects on C57BL/6J MOR-KO mice over a range
of active doses (32–64 mg/kg). Two-way ANOVA
revealed a signiﬁcant eﬀect of (¡)-tramadol on all the
behaviour studied [Table 2(s–u) ; p<0.001] and a sig-
niﬁcant eﬀect of genotype on swinging (p<0.01) and
curling (p<0.001). Interestingly, the interaction of
both factors ((¡)-tramadolrgenotype) was only sig-
niﬁcant for curling (p<0.05). To study the eﬀect of
(¡)-tramadol on diﬀerent behaviours, we performed a
one-way ANOVA, followed by the Dunnett’s test
[Table 2(v–x)]. Results showed that (¡)-tramadol
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Fig. 4. Opioid receptor involvement in the eﬀects of codeine
on immobility, curling and swinging behaviour in the tail
suspension test in mice. Codeine (40 mg/kg i.p.) and the
opioid receptor antagonist naloxone (0.5–2 mg/kg s.c.) were
administered 30 min before testing and the data represent
the mean counts+S.E.M. from 10 animals per group. There
were signiﬁcant diﬀerences when compared to saline-treated
mice (two-way analysis of variance followed by Bonferroni
post-hoc test : **p<0.01).
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signiﬁcantly decreased immobility to a similar degree
in all three genotypes (Fig. 6), although the eﬀect of
(¡)-tramadol on active behaviour varied according to
the genotype. Thus, at both doses (¡)-tramadol sig-
niﬁcantly increased swinging behaviour in knockout
mice alone (p<0.05 and p<0.01, respectively), while
curling behaviour was signiﬁcantly increased at
64 mg/kg in wild-type and heterozygous mice
(p<0.01 and p<0.001, respectively ; Fig. 6). Note that
the eﬀect of (¡)-tramadol was similar in CD1 and
C57BL/6J wild type mice (Figs. 3e, 6).
Discussion
The current study describes a modiﬁed means of
scoring the TST, which diﬀerentiates between two
active behaviours, swinging and curling. Using this
approach, it was evident that antidepressants and
opioids induce distinct active behaviours in the TST.
While antidepressants increased swinging behaviour
but had no eﬀect on curling, opioids increased curling
behaviour. Importantly, both antidepressants and
opioids diminish the immobility of the mice, the
traditional measure of antidepressant-like activity in
the TST.
Amodiﬁed form of the rat FST previously described
a behavioural sampling technique that could dis-
tinguish between antidepressants with noradrenergic
and serotonergic modes of action (Cryan et al. 2002).
Hence, we employed a similar sampling technique to
quantify and distinguish active behaviours induced by
antidepressant treatment in the TST. While the tra-
ditional method of scoring the TST only measures the
duration of immobility, we scored the frequency of the
distinct behaviours in 5-s intervals throughout the test
session. The results obtained using this approach do
not diﬀer from those obtained when each of the behav-
iours of interest are timed (Berrocoso & Mico, 2009a),
yet they provided important information on the active
behaviours that may be adopted when immobility is
reduced. Signiﬁcantly, our data are consistent with the
strain diﬀerences previously observed in the TST
(Cryan et al. 2005a ; Liu & Gershenfeld, 2001) as CD1
mice were less immobile than C57BL/6J mice. Along
similar lines, the immobility we observed in the dose–
response experiments performed was in accordance
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with the eﬀects of antidepressants observed in other
such screening tests. For example, the decrease in
immobility following 10 and 20 mg/kg venlafaxine
administration here is similar to its eﬀect on mice
in the FST (Berrocoso & Mico, 2009b). These ﬁndings
validate the behavioural sampling technique and
conﬁrm that immobility is not to be confused with
active behaviours.
The present study demonstrates that antidepressant
compounds that diﬀerentially block the reuptake of
NA and/or 5-HT induce a stereotypic behavioural
proﬁle that involves decreased immobility and in-
creased swinging, with no eﬀect on curling behaviour.
These results implicate enhanced noradrenergic
and/or serotenergic neurotransmission in swinging
behaviour. Interestingly, and in agreement with pre-
vious data regarding the poor eﬀect of SSRIs in animal
models of depression (Berrocoso &Mico, 2009a ; Lucki
et al. 2001; Petit-Demouliere et al. 2005), a much higher
dose of citalopram than that of other classes of anti-
depressants (noradenergic or dual) is required to sig-
niﬁcantly decrease immobility and increase swinging
in CD1 mice. However, this behavioural sampling
technique was unable to diﬀerentiate between anti-
depressants that selectively increase 5-HT or nor-
adrenergic neurotransmission, unlike the modiﬁed
version of the rat FST (Detke et al. 1995). It should be
noted that, to date, all behavioural patterns in mouse
tests of depression (including the FST) have been at-
tributed to either serotoninergic or catecholaminergic
signalling. The reasons for this restriction have not yet
been elucidated but it suggests that diﬀerences in the
coping strategies employed by mice and rats may be
reﬂected in distinct active behaviours.
One of the main ﬁndings in this study is the clear
demonstration of the antidepressant-like eﬀect exerted
by opioids, as witnessed by a decrease in immobility.
These ﬁndings are consistent with previous studies
using the TST or other behavioural tests to screen for
depression or antidepressant eﬀects using similar
doses of these opioids (Fichna et al. 2007; Rojas-
Corrales et al. 2002; Tejedor-Real et al. 1993, 1998). In
the learned helplessness paradigm, morphine exerts
an antidepressant-like eﬀect and is antagonized by
naloxone, indicating that it is indeed mediated by the
opioids (Besson et al. 1996; Tejedor-Real et al. 1995).
Antidepressant eﬀects of other MOR agonists, such as
(x)-methadone and levorphanol, have also been re-
ported in the rat learned helplessness test (Rojas-
Corrales et al. 2002). Thus, our ﬁndings validate the
use of the TST as a test to screen for antidepressant-
like activity of compounds that modulate opioid
neurotransmission. Furthermore, the characteristic
reduction in immobility indicative of antidepressant-
like activity was accompanied by a consistent increase
in curling behaviour with all the opioids evaluated.
The pharmacological blockade of this behaviour by
naloxone suggests that the antidepressant-like eﬀect of
opioid drugs is mediated by the opioid system and
not other neurotransmission systems. Furthermore,
the increase in curling behaviour seems to be ac-
companied by a decrease in swinging. However, it is
important to note that the observed dose-dependent
reduction in swinging may be a consequence of the
increase in curling, i.e. if the animals spend a sub-
stantial amount of the time curling then the time left
for other behaviours is reduced. While opioids caused
a 3- to 6-fold decrease in immobility at the highest
doses, swinging was only reduced y2-fold (with the
exception of morphine), indicating that many opioids
induce a shift towards relatively more swinging in the
‘non-curling’ periods. This would suggest a contri-
bution (although less relevant) of the monoaminergic
system in the antidepressant-like eﬀect of opioids.
It could be argued that curling behaviour reﬂects an
opioid-induced increase in spontaneous motor activity
or, alternatively, the induction of Straub tail, an
S-shaped dorsiﬂexion of the mouse tail, produced by
contraction of the sacro-coccygeal dorsalis muscles.
Such eﬀects would suggest that curling behaviour is
not an escape-oriented behaviour but, rather, that it
can be considered as a false positive score in the
TST. However, we previously showed that codeine
(40 mg/kg) did not modify spontaneous motor ac-
tivity or coordination (Berrocoso & Mico, 2009a). In
addition, spontaneous locomotion is not modiﬁed in
the genetic knockout of the MOR (Ide et al. 2010), rul-
ing out any possible increase in spontaneous motor
activity. While Straub tail may be produced by high
doses of opiates (Bilbey et al. 1960; Narita et al. 1993),
genetic blockade of MORs signiﬁcantly and speciﬁ-
cally decreases curling behaviour without modifying
immobility, indicating that Straub tail and curling
are modulated by diﬀerent mechanisms. Therefore, it
seems unlikely that these events are confounded in the
analysis of active behaviours in the TST.
While many studies have described antidepressant-
like eﬀects of d (Tejedor-Real et al. 1998; Torregrossa
et al. 2005, 2006) and k (Mague et al. 2003; Pliakas et al.
2001; Shirayama et al. 2004) receptor antagonists,
the speciﬁc roles of these opioid receptors on opioid-
induced behaviour was not evaluated here. Hence,
further studies with opioids that speciﬁcally act
through these receptors will be necessary to determine
their individual contributions. Indeed, since d-opioid
receptors are thought to be critical for the analgesic
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activity of tricyclic antidepressants (Benbouzid et al.
2008), it would be interesting to evaluate their possible
contribution to the eﬀect observed in the TST. Finally,
in the light of experiences with the FST (Cryan et al.
2005b), it would also be very interesting to test other
eﬀective or potential antidepressants that do not
directly target monoamines (such as ketamine, AMPA
potentiators or CRF1 antagonists) in order to deter-
mine how they aﬀect the active behaviours described
above.
We evaluated our modiﬁed scoring method using
(¡)-tramadol, a compound that has both opioid
and monoaminergic eﬀects. This compound is a weak
agonist of the MOR and, like many antidepressant
drugs, it inhibits the reuptake of 5-HT and NA. When
compared to its parental compound, (+)-tramadol
binds more potently to MOR and it inhibits the re-
uptake of 5-HT (Raﬀa et al. 1993; see Table 1). Indeed,
(¡)-tramadol decreases the immobility of CD1 mice
and is suggestive of an antidepressant-like action
(Berrocoso et al. 2006; Rojas-Corrales et al. 2002, 2004;
Yalcin et al. 2007), further validating our sampling
method. While (¡)-tramadol signiﬁcantly increased
curling behaviour (consistent with an increase in MOR
activity) it hadno eﬀect on swinging behaviour, despite
its monoaminergic mode of action. Interestingly,
(+)-tramadol, which possesses greater aﬃnity for
MOR, acted like a typical opioid, decreasing immo-
bility and swinging behaviour and increasing curling.
These data are consistent with the stronger aﬃnity
of (¡)-tramadol and (+)-tramadol for MOR than for
5-HT/NA transporters (Table 1).
The administration of (¡)-tramadol to MOR-KO
mice provided further evidence of its speciﬁc mode
of action. Thus, (¡)-tramadol showed similar anti-
depressant-like eﬀects in all three genotypes (wild-
type, heterozygous and knockout), as indicated by
the decrease in immobility. However, the increase
in curling behaviour in wild-type mice suggests that
(¡)-tramadol acts through the opioid system,
although the increase in swinging induced by (¡)-
tramadol in MOR-KO mice suggests that it enhances
monoaminergic neurotransmission. Heterozygous
mice displayed a proﬁle similar to that of wild-type
mice, indicative of a predominant opioid-mediated
eﬀect. It is also noteworthy that (¡)-tramadol does not
apparently aﬀect swinging in wild-type mice, despite
its well-known inﬂuence on monoamine transporters.
The decrease in immobility but not swinging indicates
a shift towards more swinging in the ‘non-curling’
periods. However, (¡)-tramadol-induced swinging is
more pronounced in MOR-KO mice, indicating that
curling induced by MOR activation might mask the
eﬀects on swinging. These ﬁndings demonstrate the
utility of this approach to explore the mode of action
of monoaminergic/opioidergic compounds. Further-
more, we show that (¡)-tramadol has both a central
monoaminergic and opioidergic activity and that it
can elicit antidepressant-like eﬀects, even when one of
these signalling mechanisms is blocked. This ﬁnding
may be particularly relevant in pathological con-
ditions in which both receptor proﬁles are modiﬁed.
Depression displays remarkable inter-individual
variation in terms of symptoms and drug response.
For example, opioid therapy has been successful in
treating some refractory cases of depression such
as when using the MOR agonists, oxycodone and
oxymorphone, the partial agonist, buprenorphine, and
the atypical opioid (¡)-tramadol (Bodkin et al. 1995;
Fanelli & Montgomery, 1998 ; Shapira et al. 2001;
Spencer, 2000 ; Stoll & Rueter, 1999). Accordingly,
alterations to the opioid system may underlie the
neuroendocrine abnormalities observed in some
groups of patients with this illness (Kennedy et al.
2006). Indeed, signiﬁcant alterations in MOR acti-
vation have been observed in several brain areas
(e.g. rostral region of the anterior cingulate) in patients
with a major depressive disorder who did not respond
to SSRI treatment. Interestingly, these alterations
were correlated with corticotropin and cortisol plasma
levels. Thus, although it remains to be conﬁrmed, it is
possible that the behaviour’s aﬀect in the TST could
serve to predict diﬀerent symptom clusters or thera-
peutic eﬀects.
In summary, using a novel approach to scoring
the TST, two speciﬁc active behaviours can be charac-
terized that enable serotonergic/noradrenergic
antidepressants to be distinguished from opioid com-
pounds: swinging and curling. While traditional anti-
depressants that inhibit serotonin and/orNA reuptake
decrease immobility and increase swinging behaviour,
opioids, having decreased immobility, increase curl-
ing behaviour. Analysing these active behaviours may
be useful to evaluate the mode of action of opioids and
of opioids that also display monoaminergic properties,
providing an important means of analysing the anti-
depressant eﬀects of opioid compounds.
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